Related Experiment Video
Updated: Feb 23, 2026
Author Spotlight: Investigating the Pathophysiology of Eosinophilic Esophagitis
Published on: May 10, 2024
Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease
Ian D Pavord1, Pascal Chanez1, Gerard J Criner1
1From the Respiratory Medicine Unit and Oxford Respiratory Biomedical Research Centre, Nuffield Department of Medicine, University of Oxford, Oxford (I.D.P.), and Clinical Statistics, GlaxoSmithKline, Uxbridge (B.M.) - both in the United Kingdom; the Department of Respiratory Medicine and CIC Nord, Aix-Marseille University, Marseille, France (P.C.); the Department of Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University, Philadelphia (G.J.C.); the Department of Pulmonary Medicine and Tuberculosis, University of Groningen and University Medical Center Groningen, Groningen, the Netherlands (H.A.M.K.); the Pulmonary Department, Mainz University Hospital, Mainz, Germany (S.K.); the Division of Pulmonary, Allergy, and Critical Care Medicine, Duke University, Durham (N.L.), and the Respiratory Medical Franchise (F.C.A.) and the Respiratory Therapeutic Area (E.S.B., S.S.H., D.B.R., S.W.Y.), GlaxoSmithKline, Research Triangle Park - all in North Carolina; the Department of Pneumology, Centre Hospitalier Universitaire-Université Catholique de Louvain, Namur, Namur, Belgium (J.-B.M.); the Division of Allergology and Respiratory Medicine, Showa University School of Medicine, Tokyo (H.S.); and the Department of Medicine, University of Pittsburgh, Pittsburgh (F.C.S.).
Mepolizumab treatment reduced exacerbations in patients with eosinophilic chronic obstructive pulmonary disease (COPD). This biologic therapy offers a new option for managing COPD exacerbations driven by eosinophilic airway inflammation.
Area of Science:
- Pulmonology
- Immunology
- Pharmacology
Background:
- Chronic obstructive pulmonary disease (COPD) exacerbations are a significant cause of morbidity.
- Eosinophilic phenotype in COPD patients may indicate a specific inflammatory pathway.
- Targeting interleukin-5 with mepolizumab is a potential therapeutic strategy.
Purpose of the Study:
- To evaluate the efficacy and safety of mepolizumab in reducing exacerbations in patients with COPD and an eosinophilic phenotype.
- To compare mepolizumab's effect against placebo in two Phase 3 clinical trials (METREX and METREO).
Main Methods:
- Two randomized, placebo-controlled, double-blind trials (METREX and METREO) were conducted.
- Patients received mepolizumab (100 or 300 mg) or placebo subcutaneously every 4 weeks for 52 weeks.
- Primary endpoint was the annual rate of moderate to severe COPD exacerbations; safety was also assessed.
Main Results:
- In METREX, mepolizumab (100 mg) significantly reduced exacerbations in patients with an eosinophilic phenotype (rate ratio 0.82, P=0.04).
- METREO showed a trend towards reduced exacerbations with mepolizumab (100 mg: RR 0.80, P=0.07; 300 mg: RR 0.86, P=0.14).
- Mepolizumab's efficacy was greater in patients with higher baseline blood eosinophil counts; safety profiles were similar to placebo.
Conclusions:
- Mepolizumab (100 mg) effectively lowers the rate of exacerbations in COPD patients with an eosinophilic phenotype.
- Eosinophilic airway inflammation plays a role in COPD exacerbations.
- Mepolizumab represents a targeted therapy option for this patient subgroup.
Related Concept Videos
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:26COPD: Management Using Bronchodilators and Corticosteroids
01:29Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
01:17Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
01:24Chronic Obstructive Pulmonary Disease
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...